Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II trial of the Gynecologic Oncology Group.
Twenty-two patients with recurrent carcinoma of the ovary progressive after initial chemotherapy (21 with cisplatin-based treatment) were entered on a phase II trial utilizing Echinomycin at a dosage of 1,500 micrograms/m2 every 4 weeks. There were two complete responders and no partial responders (9% response, 95% confidence intervals for complete and partial responses of 1-29%). Major toxicity was modest and consisted mainly of nausea and vomiting. Echinomycin displays minimal activity as salvage therapy in women with advanced ovarian cancer at this dose and schedule.
Muss
H B
HB
Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Blessing
J A
JA
Baker
V V
VV
Barnhill
D R
DR
Adelson
M D
MD
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D004448:Echinomycin / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011810:Quinoxalines / Q000627:therapeutic use*; D012074:Remission Induction
D011810:Quinoxalines; D004448:Echinomycin